美国新展科技投资计划.doc

美国新展科技投资计划执行摘要 高新生物科技项目 ? 固化一氧化氮技术平台 联络人：陈以三 首席运营官 新展科技(美国)有限公司 One Technology Drive, Suite B-115 Irvine, CA 92618 USA T: +86 150E: nelson.tan@ W: April 2012 [Disclaimer] This Investment Plan Executive Summary (“Plan”) was prepared by SynZyme Technologies LLC (“SynZyme”) and is being delivered to a limited number of investors and stakeholders who may be interested in pursuing an investment in SynZyme or SynZyme-initiated business opportunities (“Transaction”). The sole purpose of this Plan is to assist the recipient in deciding whether to proceed with a further investigation of the Transaction. This Plan does not purport to be all-inclusive or to contain all the information that an interested party may desire in investigating SynZyme or the Transaction. This Plan has been prepared for informational purposes relating to a possible Transaction only and upon the express understanding that it will be used only for the purposes set forth above. In all cases, interested parties should conduct their own investigation and analysis of SynZyme and the data set forth in this Plan. SynZyme makes no express or implied representation or warranty as to the accuracy or completeness of the information contained herein or delivered herewith. SynZyme expressly disclaims any and all liability which may be based on such information, errors therein or omissions thereafter. The recipient shall be entitled to rely solely on the representations and warranties made to it in any purchase agreement and any other documents relating thereto, as and if executed, and subject to such limitations and restrictions as may be specified in such agreement. In furnishing this Plan, SynZyme undertakes no obligation to provide the recipient with access to any additional information. 美国新展科技有限公司(SynZym Technologies LLC，新展科技)是一家私营、注册于美国的药物发现和药物开发公司，其使命是成为全球调节血液一氧化氮新型治疗药物的领先制造商。血管内靶向传送固化一氧化氮(Caged Nitric Oxide，cNO)用于调节血管内一氧化氮的活性这一世界领先的生物科技技术平台是由新展科技独家发明。 新展一氧化氮NO)修饰治疗药物的基础是具备简单催化酶模仿生物或非生物